Trial record 1 of 13 for:    "sitosterolemia" OR "beta-sitosterolemia" OR "phytosterolaemia" OR "sitosterolaemia" OR "Mediterranean stomatocytosis macrothrombocytopenia"
Previous Study | Return to List | Next Study

Sitosterolemia Metabolism (STAIR7002)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University of Manitoba
ClinicalTrials.gov Identifier:
NCT01584206
First received: April 16, 2012
Last updated: March 9, 2016
Last verified: December 2015
  Purpose
Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.

Condition Intervention
Sitosterolemia
Drug: Ezetimibe

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe

Resource links provided by NLM:


Further study details as provided by University of Manitoba:

Primary Outcome Measures:
  • Plasma cholesterol level [ Time Frame: 8 months ] [ Designated as safety issue: Yes ]
    Plasma cholesterol level will be assessed by GC

  • Plasma sitosterol level [ Time Frame: 8 months ] [ Designated as safety issue: Yes ]
    Plasma plant sterol assessment using GC


Secondary Outcome Measures:
  • Cholesterol absorption [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    Use stable isotope technique to assess cholesterol absorption

  • Cholesterol synthesis [ Time Frame: 4 months ] [ Designated as safety issue: No ]
    Use of stable isotope to assess cholesterol synthesis.


Enrollment: 8
Study Start Date: April 2012
Estimated Study Completion Date: December 2016
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ezetimibe
Compare on and off ezetimibe
Drug: Ezetimibe
10mg ezetimibe/day, at least 4 months

  Eligibility

Ages Eligible for Study:   16 Years to 99 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • confirmed diagnosis of homozygous sitosterolemia as established by genotyping and clinical parameters

Exclusion Criteria:

  • pregnant
  • intellectual disability
  • major infectious diseases
  • immunodeficiency
  • cancer
  • renal failure
  • diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01584206

Locations
Canada, Manitoba
Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba, Canada, R3T 2N2
Sponsors and Collaborators
University of Manitoba
Investigators
Principal Investigator: Semone B Myrie, PhD University of Manitoba
Study Chair: Peter J Jones, PhD University of Manitoba
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Manitoba
ClinicalTrials.gov Identifier: NCT01584206     History of Changes
Other Study ID Numbers: B2011:051 
Study First Received: April 16, 2012
Last Updated: March 9, 2016
Health Authority: Canada: Ethics Review Committee
United States: Institutional Review Board

Keywords provided by University of Manitoba:
Sitosterolemia
Ezetimibe
Plant sterol
Cholesterol

Additional relevant MeSH terms:
Hypercholesterolemia
Intestinal Diseases
Lipid Metabolism, Inborn Errors
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Ezetimibe
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents

ClinicalTrials.gov processed this record on July 25, 2016